Personalizing adjuvant therapy for patients with colorectal cancer

Yang, Li; Yang, Jinlin; Kleppe, Andreas; Danielsen, Håvard E.; Kerr, David J.

doi:10.1038/s41571-023-00834-2

Cited by 17 publications

(1 citation statement)

References 109 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Artificial intelligence-driven models applied to digital photographs of removed tissue have revealed potentially helpful algorithms in the last few years that categorize patients into different prognosis groupings. Likewise, methods such as liquid biopsy, which gauges the amount of DNA from circulating tumors after surgery, can also be helpful in determining which patients have a high or low risk of their tumors returning [8].…”

Section: Figure 3: Frequency and Percentage Of Postoperative Complica...mentioning

confidence: 99%

A Clinical Study of Intraoperative Perfusion Chemotherapy With Raltitrexed in Colon Cancer: A Prospective Cohort

Adnan,

Hussain,

Amir

et al. 2024

Cureus

View full text Add to dashboard Cite

Introduction: Colorectal cancer (CRC) ranks as the second leading cause of cancer-related mortality among women and the third leading cause of cancer-associated mortality among men. Treatment of colon cancer is very crucial for a patient's survival. In this study, we assessed the reliability, efficacy, and safety of raltitrexed in intraoperative intraperitoneal chemotherapy for colon cancer.Methodology: A total of 57 patients with clinical stages II and III of colon cancer were included in the study. R0 resection surgery + hyperthermic intraperitoneal chemotherapy (HIPEC) procedure was done with raltitrexed. It was given in a dose of 3 mg/m 2 in a 0.9% NS injection in a volume of 500 milliliters. Postoperative complications were observed.Result: The most common postoperative complication was nausea/vomiting, which was seen in 21 out of 57 patients (37%). The second most common complication was fever (18/57). None of the patients died or developed renal toxicity, hepatic toxicity, and intestinal obstruction.Conclusion: Raltitrexed is a reliable, efficient, and safe drug and can be used in intraoperative intraperitoneal chemotherapy of colon cancer.

show abstract

Section: Figure 3: Frequency and Percentage Of Postoperative Complica...mentioning

confidence: 99%

A Clinical Study of Intraoperative Perfusion Chemotherapy With Raltitrexed in Colon Cancer: A Prospective Cohort

Adnan,

Hussain,

Amir

et al. 2024

Cureus

View full text Add to dashboard Cite

show abstract

A Biomimetic Autophagosomes‐Based Nanovaccine Boosts Anticancer Immunity

Qu,

Cui,

Sun

et al. 2024

Advanced Materials

View full text Add to dashboard Cite

Personalized cancer vaccines based on tumor cell lysates offer promise for cancer immunotherapy yet fail to elicit a robust therapeutic effect due to the weak immunogenicity of tumor antigens. Autophagosomes, obtained from pleural effusions and ascites of cancer patients, have been identified as abundant reservoirs of tumor neoantigens that exhibit heightened immunogenicity. However, their potential as personalized cancer vaccines have been constrained by suboptimal lymphatic‐targeting performances and challenges in antigen‐presenting cell endocytosis. Here,a reinforced biomimetic autophagosome‐based (BAPs) nanovaccine generated by precisely amalgamating autophagosome‐derived neoantigens and two types of adjuvants capable of targeting lymph nodes is developed to potently elicit antitumor immunity. The redox‐responsive BAPs facilitate cytosolic vaccine opening within antigen‐presenting cells, thereby exposing adjuvants and antigens to stimulate a strong immune response. BAPs evoke broad‐spectrum T‐cell responses, culminating in the effective eradication of 71.4% of established tumors. Notably, BAPs vaccination triggers enduring T‐cell responses that confer robust protection, with 100% of mice shielded against tumor rechallenge and a significant reduction in tumor incidence by 87.5%. Furthermore, BAPs synergize with checkpoint blockade therapy to inhibit tumor growth in the poorly immunogenic breast cancer model. The biomimetic approach presents a powerful nanovaccine formula with high versatility for personalized cancer immunotherapy.

show abstract